Extensively drug-resistant tuberculosis in California, 1993-2006

Ritu Banerjee, Jennifer Allen, Janice Westenhouse, Peter Oh, William Elms, Ed Desmond, Annette Nitta, Sarah Royce, Jennifer Flood

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Background. Extensively drug-resistant (XDR) tuberculosis (TB) is a global public health emergency. We investigated the characteristics and extent of XDR TB in California to inform public health interventions. Methods. XDR TB was defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone, and 1 of 3 injectable second-line drugs (amikacin, kanamycin, or capreomycin). Pre-XDR TB was defined as TB with resistance to isoniazid and rifampin and either a fluoroquinolone or second-line injectable agent but not both. We analyzed TB case reports submitted to the state TB registry for the period 1993-2006. Local health departments and the state TB laboratory were queried to ensure complete drug susceptibility reporting. Results. Among 424 multidrug-resistant (MDR) TB cases with complete drug susceptibility reporting, 18 (4.2%) were extensively drug resistant, and 77 (18%) were pre-extensively drug resistant. The proportion of pre-XDR TB cases increased over time, from 7% in 1993 to 32% in 2005 (P = .02). Among XDR TB cases, 83% of cases involved foreign-born patients, and 43% were diagnosed in patients within 6 months after arrival in the United States. Mexico was the most common country of origin. Five cases (29%) of XDR TB were acquired during therapy in California. All patients with XDR TB had pulmonary disease, and most had prolonged infectious periods; the median time for conversion of sputum culture results was 195 days. Among 17 patients with known outcomes, 7 (41.2%) completed therapy, 5 (29.4%) moved, and 5 (29.4%) died. One patient continues to receive treatment. Conclusions. XDR TB and pre-XDR TB cases comprise a substantial fraction of MDR TB cases in California, indicating the need for interventions that improve surveillance, directly observed therapy, and rapid drug susceptibility testing and reporting.

Original languageEnglish (US)
Pages (from-to)450-457
Number of pages8
JournalClinical Infectious Diseases
Volume47
Issue number4
DOIs
StatePublished - Aug 15 2008
Externally publishedYes

Fingerprint

Extensively Drug-Resistant Tuberculosis
Tuberculosis
Pharmaceutical Preparations
Multidrug-Resistant Tuberculosis
Fluoroquinolones
Isoniazid
Rifampin
Capreomycin
Public Health
Directly Observed Therapy
Injections
Kanamycin
Amikacin

ASJC Scopus subject areas

  • Immunology

Cite this

Banerjee, R., Allen, J., Westenhouse, J., Oh, P., Elms, W., Desmond, E., ... Flood, J. (2008). Extensively drug-resistant tuberculosis in California, 1993-2006. Clinical Infectious Diseases, 47(4), 450-457. https://doi.org/10.1086/590009

Extensively drug-resistant tuberculosis in California, 1993-2006. / Banerjee, Ritu; Allen, Jennifer; Westenhouse, Janice; Oh, Peter; Elms, William; Desmond, Ed; Nitta, Annette; Royce, Sarah; Flood, Jennifer.

In: Clinical Infectious Diseases, Vol. 47, No. 4, 15.08.2008, p. 450-457.

Research output: Contribution to journalArticle

Banerjee, R, Allen, J, Westenhouse, J, Oh, P, Elms, W, Desmond, E, Nitta, A, Royce, S & Flood, J 2008, 'Extensively drug-resistant tuberculosis in California, 1993-2006', Clinical Infectious Diseases, vol. 47, no. 4, pp. 450-457. https://doi.org/10.1086/590009
Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clinical Infectious Diseases. 2008 Aug 15;47(4):450-457. https://doi.org/10.1086/590009
Banerjee, Ritu ; Allen, Jennifer ; Westenhouse, Janice ; Oh, Peter ; Elms, William ; Desmond, Ed ; Nitta, Annette ; Royce, Sarah ; Flood, Jennifer. / Extensively drug-resistant tuberculosis in California, 1993-2006. In: Clinical Infectious Diseases. 2008 ; Vol. 47, No. 4. pp. 450-457.
@article{c23fb50a5e904c06aad978a26e272938,
title = "Extensively drug-resistant tuberculosis in California, 1993-2006",
abstract = "Background. Extensively drug-resistant (XDR) tuberculosis (TB) is a global public health emergency. We investigated the characteristics and extent of XDR TB in California to inform public health interventions. Methods. XDR TB was defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone, and 1 of 3 injectable second-line drugs (amikacin, kanamycin, or capreomycin). Pre-XDR TB was defined as TB with resistance to isoniazid and rifampin and either a fluoroquinolone or second-line injectable agent but not both. We analyzed TB case reports submitted to the state TB registry for the period 1993-2006. Local health departments and the state TB laboratory were queried to ensure complete drug susceptibility reporting. Results. Among 424 multidrug-resistant (MDR) TB cases with complete drug susceptibility reporting, 18 (4.2{\%}) were extensively drug resistant, and 77 (18{\%}) were pre-extensively drug resistant. The proportion of pre-XDR TB cases increased over time, from 7{\%} in 1993 to 32{\%} in 2005 (P = .02). Among XDR TB cases, 83{\%} of cases involved foreign-born patients, and 43{\%} were diagnosed in patients within 6 months after arrival in the United States. Mexico was the most common country of origin. Five cases (29{\%}) of XDR TB were acquired during therapy in California. All patients with XDR TB had pulmonary disease, and most had prolonged infectious periods; the median time for conversion of sputum culture results was 195 days. Among 17 patients with known outcomes, 7 (41.2{\%}) completed therapy, 5 (29.4{\%}) moved, and 5 (29.4{\%}) died. One patient continues to receive treatment. Conclusions. XDR TB and pre-XDR TB cases comprise a substantial fraction of MDR TB cases in California, indicating the need for interventions that improve surveillance, directly observed therapy, and rapid drug susceptibility testing and reporting.",
author = "Ritu Banerjee and Jennifer Allen and Janice Westenhouse and Peter Oh and William Elms and Ed Desmond and Annette Nitta and Sarah Royce and Jennifer Flood",
year = "2008",
month = "8",
day = "15",
doi = "10.1086/590009",
language = "English (US)",
volume = "47",
pages = "450--457",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Extensively drug-resistant tuberculosis in California, 1993-2006

AU - Banerjee, Ritu

AU - Allen, Jennifer

AU - Westenhouse, Janice

AU - Oh, Peter

AU - Elms, William

AU - Desmond, Ed

AU - Nitta, Annette

AU - Royce, Sarah

AU - Flood, Jennifer

PY - 2008/8/15

Y1 - 2008/8/15

N2 - Background. Extensively drug-resistant (XDR) tuberculosis (TB) is a global public health emergency. We investigated the characteristics and extent of XDR TB in California to inform public health interventions. Methods. XDR TB was defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone, and 1 of 3 injectable second-line drugs (amikacin, kanamycin, or capreomycin). Pre-XDR TB was defined as TB with resistance to isoniazid and rifampin and either a fluoroquinolone or second-line injectable agent but not both. We analyzed TB case reports submitted to the state TB registry for the period 1993-2006. Local health departments and the state TB laboratory were queried to ensure complete drug susceptibility reporting. Results. Among 424 multidrug-resistant (MDR) TB cases with complete drug susceptibility reporting, 18 (4.2%) were extensively drug resistant, and 77 (18%) were pre-extensively drug resistant. The proportion of pre-XDR TB cases increased over time, from 7% in 1993 to 32% in 2005 (P = .02). Among XDR TB cases, 83% of cases involved foreign-born patients, and 43% were diagnosed in patients within 6 months after arrival in the United States. Mexico was the most common country of origin. Five cases (29%) of XDR TB were acquired during therapy in California. All patients with XDR TB had pulmonary disease, and most had prolonged infectious periods; the median time for conversion of sputum culture results was 195 days. Among 17 patients with known outcomes, 7 (41.2%) completed therapy, 5 (29.4%) moved, and 5 (29.4%) died. One patient continues to receive treatment. Conclusions. XDR TB and pre-XDR TB cases comprise a substantial fraction of MDR TB cases in California, indicating the need for interventions that improve surveillance, directly observed therapy, and rapid drug susceptibility testing and reporting.

AB - Background. Extensively drug-resistant (XDR) tuberculosis (TB) is a global public health emergency. We investigated the characteristics and extent of XDR TB in California to inform public health interventions. Methods. XDR TB was defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone, and 1 of 3 injectable second-line drugs (amikacin, kanamycin, or capreomycin). Pre-XDR TB was defined as TB with resistance to isoniazid and rifampin and either a fluoroquinolone or second-line injectable agent but not both. We analyzed TB case reports submitted to the state TB registry for the period 1993-2006. Local health departments and the state TB laboratory were queried to ensure complete drug susceptibility reporting. Results. Among 424 multidrug-resistant (MDR) TB cases with complete drug susceptibility reporting, 18 (4.2%) were extensively drug resistant, and 77 (18%) were pre-extensively drug resistant. The proportion of pre-XDR TB cases increased over time, from 7% in 1993 to 32% in 2005 (P = .02). Among XDR TB cases, 83% of cases involved foreign-born patients, and 43% were diagnosed in patients within 6 months after arrival in the United States. Mexico was the most common country of origin. Five cases (29%) of XDR TB were acquired during therapy in California. All patients with XDR TB had pulmonary disease, and most had prolonged infectious periods; the median time for conversion of sputum culture results was 195 days. Among 17 patients with known outcomes, 7 (41.2%) completed therapy, 5 (29.4%) moved, and 5 (29.4%) died. One patient continues to receive treatment. Conclusions. XDR TB and pre-XDR TB cases comprise a substantial fraction of MDR TB cases in California, indicating the need for interventions that improve surveillance, directly observed therapy, and rapid drug susceptibility testing and reporting.

UR - http://www.scopus.com/inward/record.url?scp=48749094870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48749094870&partnerID=8YFLogxK

U2 - 10.1086/590009

DO - 10.1086/590009

M3 - Article

C2 - 18616396

AN - SCOPUS:48749094870

VL - 47

SP - 450

EP - 457

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -